B
ACRS icon

Braidwell’s Aclaris Therapeutics ACRS Stock Holding History

Braidwell’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
2,142,348
+443,232
+26% +$1.98M 0.42% 67
2026
Q1 		$6.37M Buy
+1,699,116
New +$5.73M 0.21% 79
2023
Q3 		– Sell
-2,901,194
Closed -$30.1M – 86
2023
Q2 		$30.1M Sell
2,901,194
-367,900
-11% -$3.33M 0.98% 36
2023
Q1 		$26.4M Buy
3,269,094
+875,109
+37% +$11.1M 0.87% 47
2022
Q4 		$37.7M Buy
+2,393,985
New +$38.5M 1.26% 27

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Braidwell's ACRS Position: Q2 2026 in Review

Braidwell increased its Aclaris Therapeutics (ACRS) stake by 26% in Q2 2026, buying an estimated $1.98M and bringing the position to 2,142,348 shares worth $11.3M. The position accounts for 0.42% of the portfolio, ranked #67.

Braidwell first reported a position in ACRS in Q4 2022 and has held it in 5 quarters since. The position peaked at $37.7M in Q4 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Braidwell held 2,142,348 shares of Aclaris Therapeutics worth $11.3M as of Q2 2026.
  • Braidwell bought 443,232 Aclaris Therapeutics shares in Q2 2026, an estimated $1.98M.
  • Aclaris Therapeutics made up 0.42% of Braidwell's portfolio in Q2 2026, its #67 holding.
  • Braidwell first reported a position in Aclaris Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • Braidwell's Aclaris Therapeutics position peaked at $37.7M in Q4 2022.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.